Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetirizine for interferon beta-associated flu-like syndrome in relapsing-remitting multiple sclerosis
2013-001055-12Phase 3Completed
- Sponsor
- Biogen
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cetirizine in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoints: Average variation in flu-like syndrome severity score, Proportion of patients with average decrease of at least 2 points in flu-like syndrome score and 1 more. Started Jun 2013; status: completed.
02
Drugs
cetirizine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-001055-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001055-12.